Selecting First-Line Therapy Based on Disease Biology and Risk

This segment addresses how clinicians approach first-line treatment selection in advanced RCC, particularly in the context of available combination regimens. The discussion centers on choosing between dual immune checkpoint blockade and combinations of immunotherapy with VEGF-targeted TKIs. Dr. Campbell explains that decision-making is heavily influenced by disease characteristics, including metastatic burden and sites of involvement, as well as the urgency of achieving disease control. Patients with aggressive or symptomatic disease may benefit from regimens that provide rapid tumor reduction, while those with more indolent disease may be candidates for approaches that prioritize durability of response. Dr. Voss adds that treatment goals, including depth and duration of response, must be balanced against tolerability and long-term planning. The segment emphasizes that most patients will ultimately require additional therapy, making the availability of effective second-line options a key consideration even at the time of initial treatment selection.